A GLP-1 weight-loss program is a multi-month commitment, so it should be marketed with a consult offer, not a lead buy and not the drug by name. Naming a prescription GLP-1 on Meta needs certification and authorization, and personal-attribute copy gets rejected, so the compliant and better-converting move is to sell a medical weight-loss consultation. One enrolled patient is worth months of program revenue, not a single visit. The ad books the consult, the consult enrolls the patient, and you judge the whole thing on cost per enrolled patient against the value of that program.
Key numbers
- Naming a prescription GLP-1 on Meta requires LegitScript certification plus Meta authorization, or the ad is generally rejected.
- Meta rejects personal-attribute copy: "struggling with your weight?" asserts something about the viewer and fails review.
- As of July 22, 2026, Meta stopped auto-rejecting weight-loss and cosmetic before-and-afters, but the claims decide the outcome, and photos need patient authorization on file.
- Meta classifies your landing-page URL too, so a path like /semaglutide-weight-loss can trigger review even with clean ad text.
- Nice med spa: EUR 620 of ad budget, 193 leads at EUR 3.21 each, 88 clients, first lead answered 1h27 after launch.
A med spa adds a weight-loss program and wants it full fast. So it buys a batch of weight-loss leads from a vendor, a few hundred names, and starts dialing.
The calls go badly. Half the numbers are cold, the ones who answer were quoted a lower first-month price by two other clinics an hour ago, and almost nobody wants to talk about a six-month plan. A handful start, most of those vanish after the first refill.
The program limps along, and the owner decides "weight loss doesn't work for us." It wasn't the program. It was buying the least-committed patients on the market and selling them the cheapest slice of a long treatment.
A GLP-1 program is not an impulse buy. It runs for months, and marketing it like a one-time deal throws away the part of the patient that is actually worth money.
What should a GLP-1 weight-loss ad actually sell?
The consult. Not the drug, not a number on the scale, not a discounted first month. A medical assessment.
Here is why that is both the smarter offer and the safer one. A GLP-1 program depends on a clinician looking at the individual patient, their health history, and their goals. So the honest offer is a consultation where a professional assesses them and recommends a plan. That converts better than a generic promise, because it meets people where they are: curious, a little nervous, wanting someone qualified to tell them whether this is right for them.
It is also the offer that keeps your ad account alive. On most platforms you cannot name a prescription GLP-1 without certification, you cannot assert a personal attribute like "struggling with your weight?", and you cannot promise a specific result. A consult ad makes none of those claims, so there is nothing to reject. It is the same consult-first logic that protects any medical treatment, which is why the compliant way to run GLP-1 ads is to sell the assessment, not the medication. That post covers the rule set in detail. This one is about the economics underneath it.
Why can't you just name the drug in the ad?
Because the platforms treat a prescription GLP-1 as regulated health advertising, and they enforce it.
On Meta, promoting a prescription GLP-1 by name requires LegitScript certification plus Meta's written authorization. Without it, an ad that references the drug is generally rejected. And it goes further than the ad text: Meta also classifies your landing-page URL and domain, so a path like /semaglutide-weight-loss, or a product name reading "GLP-1 Metabolic Support," can trigger review even when the ad itself never mentions a drug. Google runs a different rulebook, so if you advertise there, check its certification rules separately rather than assuming they match.
There was one real change worth knowing. As of July 22, 2026, Meta no longer rejects weight-loss and cosmetic before-and-after imagery on sight. But do not read that as open season. The claims around the image still decide the outcome, transformation photos still need patient authorization on file, and any language implying a guaranteed result still fails. The safest, highest-converting path has not changed: offer a consult, make no claim, and let the clinician do the rest in the room.
Why does buying weight-loss leads backfire?
Because the program needs committed patients, and bought leads select for the opposite.
A purchased weight-loss lead is usually shared across several clinics and sold cold. So you are not the only call, and the person is comparing first-month prices in real time. That attracts the patient least likely to stay for a months-long program: the one shopping for the cheapest start, who takes the deal and drifts after the first refill. You pay full acquisition cost and capture a fraction of the value.
The fix is the same one that works for every high-commitment med spa service: own the demand instead of renting it. We made this case for building your own patient pipeline instead of buying leads, and a GLP-1 program is the clearest example of why it matters. When you run your own consult ads to a landing page you own, the inquiries are exclusive, they build a list you keep, and the cost drops as the system learns who actually enrolls.
What is a GLP-1 program patient actually worth?
A program, not an appointment. And that one shift changes every number.
A medically supervised weight-loss program runs for months. There is the consult, the plan, the follow-up visits, the refills, the check-ins. One enrolled patient is worth that whole arc, plus whatever else they book at your spa once they trust you. So when you measure your ad, you measure cost per enrolled patient against the value of the program, never against the price of month one.
Here is the trap, laid out as two spas running the same ad.
| | Spa A: buys leads, sells month one | Spa B: runs consult ads, enrolls patients | |---|---|---| | Source | Shared, bought weight-loss leads | Own consult ads, exclusive inquiries | | Offer | Discounted first month | Consult, then a supervised program | | Who starts | Price-shoppers, many don't commit | Patients who want the outcome | | Patients still on at month three | Few | Most | | Value per acquired patient | One cheap month | A multi-month program plus add-ons | | Account risk | High (drug names, claims) | Low (consult, no claim) |
Say Spa B's cost per enrolled patient is $150. Against a single discounted month that feels steep. Against a six-month program worth well over a thousand dollars, it is noise. Same enrollment, completely different math, because of what the enrollment leads to. If you cannot say what an enrolled patient costs you today, that is the first thing worth pulling apart, before you spend another euro on leads.
How do you actually fill the program?
Book the consult with the ad. Enroll the patient in the room. Keep them with follow-up.
The ad's only job is to put a serious consult on the calendar. The plan gets built in person, by a clinician the patient already half-trusts because they are sitting across from them, with a real assessment. That is the sequence that works, and it is the one that keeps your account compliant, because the ad never made a promise.
Then do not let them leak. The biggest loss in any program is the patient who starts and quietly stops. Book the next visit before they leave, text a reminder before each check-in, and set a refill prompt so nobody falls off between months. None of that is ad spend. It is follow-up, and the patients you already paid to acquire are the cheapest revenue you have.
That is the mechanism, and it is not unique to weight loss. For a med spa we work with in Nice, EUR 620 of ad budget produced 193 leads at EUR 3.21 each and 88 clients. The ads booked the consults. What turned those consults into 88 clients, and kept them, was fast follow-up and a rebooking habit, with the first lead answered 1h27 after launch. Same engine, pointed at a program instead of a single treatment.
Should you ever run a discounted first-month offer?
Sometimes, on one condition: the full program gets discussed in the room.
A lower first-month price can ease a nervous first-timer in, as long as your team treats it as the start of a supervised plan, not the whole transaction. The first month is the trial. The program is the product. If nobody walks the patient through the next five months, you are just buying price-shoppers at a high delivery cost, which is exactly the trap buying leads puts you in.
The test is simple. Does the first visit end with a plan and the next appointment booked? If yes, run the intro. If no, you are paying premium prices to fill a bucket with a hole in it.
30-Second Audit
Three honest questions about your GLP-1 marketing. Answer yes or no.
- Does your ad sell a consult, or does it name the drug or promise a result on the image?
- Do you measure cost per enrolled patient against the value of the whole program, not the first month?
- When a patient starts, is their next visit on the calendar before they leave, with a refill reminder set?
If any answer was no, the fix isn't a bigger ad budget or a bigger lead buy. It's the offer and the follow-up. Book a free audit and we'll show you what an enrolled patient is actually worth across the program, even if you keep running everything yourself.
A lead buy fills a list. A consult fills the program for the year.